Efficacy and Safety of Multiple Switches From the Originator Infliximab to Biosimilars in IBD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study
Inflamm. Bowel Dis. 2022 Mar 30;28(4)495-501, J Hanzel, JM Jansen, RWF Ter Steege, KB Gecse, GR D'HaensFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.